The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia
Open accessAbstract
Purpose: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with clinical resistance to imatinib mesylate in chronic myeloid leukemia (CML) patients. To shed further light on the frequency, distribution, and prognostic significance of ABL mutations, we retrospectively analyzed a homogeneous cohort of late chronic phase CML patients who showed primary cytogenetic resistance to imatinib. Patients and Methods: Using denaturing high-performance liquid chromatography (D-HPLC) and sequencing, we screened for ABL mutations in a total of 178 bone marrow and/or peripheral blood samples from 40 late chronic phase CML patients homogeneously treated with imatinib 400 mg/d, who did not reach a major cytogenetic response at 12 months. Results: Mutations were found in 19 of 40 patients (48%). Mutations were already detectable by D-HPLC at a median of 3 months from the onset of therapy. The presence of a missense mutation was significantly associated with a greater likelihood of subsequent progression to accelerated phase/blast crisis (P = .0002) and shorter survival (P = .001). Patients carrying mutations falling within the P-loop seemed to have a particularly poor outcome in terms of time to progression (P = .032) and survival (P = .045). Conclusion: Our results show that, irrespective of the hematologic response, monitoring for emerging mutations in the first months of therapy may play a role in detecting patients with worse prognosis, for whom a revision of the therapeutic strategy should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Talpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,019
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K., Herrmann, R., Seymour, J. F., Arthur, C., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2896 · Cited by 765
Denaturing high-performance liquid chromatography: A review
Xiao, W., & Oefner, P. J. (2001) · Human Mutation · doi:10.1002/humu.1130 · Cited by 725
Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649
Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Laı̈, J.-L., Philippe, N., Facon, T., Fenaux, P., & Preudhomme, C. (2002) · Blood · doi:10.1182/blood.v100.3.1014 · Cited by 515
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
Deininger, M. W. N., Goldman, J. M., Lydon, N., & Melo, J. V. (1997) · Blood · doi:10.1182/blood.v90.9.3691 · Cited by 482
von Bubnoff, N., Schneller, F., Peschel, C., & Duyster, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07679-1 · Cited by 464
Gambacorti-Passerini, C., le Coutre, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nicola, M., Biondi, A., Corneo, G. M., Belotti, D., et al. (1997) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.1997.0155 · Cited by 316
Corbin, A. S., Rosée, P. L., Stoffregen, E. P., Druker, B. J., & Deininger, M. W. (2003) · Blood · doi:10.1182/blood-2002-12-3659 · Cited by 258
Roumiantsev, S., Shah, N. P., Gorre, M. E., Nicoll, J., Brasher, B. B., Sawyers, C. L., & Van Etten, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162140299 · Cited by 253
Hofmann, W.-K., Jones, L. C., Lemp, N. A., de Vos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O. G., & Koeffler, H. P. (2002) · Blood · doi:10.1182/blood.v99.5.1860 · Cited by 239
O'Hare, T., Pollock, R., Stoffregen, E. P., Keats, J. A., Abdullah, O. M., Moseson, E. M., Rivera, V. M., Tang, H., Metcalf, C. A., Bohacek, R. S., et al. (2004) · Blood · doi:10.1182/blood-2004-05-1851 · Cited by 200
Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571
Corbin, A. S., Buchdunger, E., Pascal, F., & Druker, B. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111525200 · Cited by 162
STI571: A Paradigm of New Agents for Cancer Therapeutics
Mauro, M. J., O'Dwyer, M. E., Heinrich, M. C., & Druker, B. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.325 · Cited by 127
Hofmann, W., Komor, M., Waßmann, B., Jones, L. C., Gschaidmeier, H., Hoelzer, D. F., Koeffler, H. P., & Ottmann, O. G. (2003) · Blood · doi:10.1182/blood-2002-06-1756 · Cited by 124
Soverini, S., Martinelli, G., Amabile, M., Poerio, A., Bianchini, M., Rosti, G., Pane, F., Saglio, G. N., Baccarani, M., the Italian Cooperative Study Group on Chronic Myeloid Leukemia (icsg-cml), et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.031112 · Cited by 120
Self-citationKreuzer, K. ‐., le Coutre, P., Landt, O., Na, I., Schwarz, M., Schultheis, K., Hochhaus, A., & Dörken, B. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0644-y · Cited by 87
Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography
Deininger, M. W., McGreevey, L. S., Willis, S. G., Bainbridge, T., Druker, B. J., & Heinrich, M. C. (2004) · Leukemia · doi:10.1038/sj.leu.2403307 · Cited by 70
Böhmer, F., Karagyozov, L. K., Uecker, A., Serve, H. L., Botzki, A., Mahboobi, S., & Dove, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209861200 · Cited by 61
Sawyers, C. L., Shah, N. P., Kantarjian, H. M., Donato, N. J., Nicoll, J. M., Bai, S. A., Huang, F., Clark, E. A., DeCillis, A. P., & Talpaz, M. (2004) · Blood · doi:10.1182/blood.v104.11.1.1 · Cited by 53
Kreuzer, K.-A., le Coutre, P., Landt, O., Na, I.-K., Schwarz, M., Schultheis, K., Hochhaus, A., & D�rken, B. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0690-5 · Cited by 48
Giles, F. J., Kantarjian, H. M., Waßmann, B., Cortes, J. E., O'Brien, S. M., Tanaka, C., Rae, P., Mietlowski, W. L., Romano, A., Alland, L., et al. (2004) · Blood · doi:10.1182/blood.v104.11.22.22 · Cited by 34
An Activating Mutation in the ATP Binding Site of the ABL Kinase Domain
Allen, P. B., & Wiedemann, L. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19585 · Cited by 33
Crystal Structure of the c-Abl Kinase domain in complex with PD173955
Nagar, B., Bornmann, W., Pellicena, P., Schindler, T., Veach, D. R., Miller, W. T., Clarkson, B., & Kuriyan, J. (2002) · Worldwide Protein Data Bank · doi:10.2210/pdb1m52/pdb · Cited by 30
Imatinib: A targeted clinical drug development
Capdeville, R., & Silberman, S. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70015-8 · Cited by 26
ADAMTS-13, VWF, inflammation, and thrombosis
Motto, D. G. (2004) · Blood · doi:10.1182/blood-2004-04-1438 · Cited by 13
(2002) · PubMed
Cited by
Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
Self-citationHughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás-Cardama, A., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 745
Mechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 643
Metadata
- Authors
- Soverini, S., Martinelli, G., Rosti, G., Bassi, S., Amabile, M., Poerio, A., Giannini, B., Trabacchi, E., Castagnetti, F., Testoni, N., Luatti, S., de Vivo, A., Cilloni, D., Izzo, B., Fava, M., Abruzzese, E., Alberti, D., Pane, F., Saglio, G., & Baccarani, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-06-20
- Volume
- 23
- Issue
- 18
- Pages
- 4100-4109
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2117569938
- Cited by
- 374
- References
- 35
- FWCI
- 21.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.